Attovia Therapeutics, Inc. (NASDAQ: ATTO) is showing a fresh cluster of insider buying, with Redmile Group, LLC — a 10%+ owner of the company — disclosing an open-market purchase of 200,000 shares at $17.00 per share on August 6, 2026. The transaction, filed on Form 4, totaled $3,400,000 and brings Redmile Group’s directly held stake to 982,854 shares.
This purchase did not happen in isolation. According to SEC filings, it is one of two open-market purchases in Attovia stock dated August 6, 2026, with the combined value of the two transactions reaching $10,200,000. Multiple insiders putting fresh capital into the same stock on the same day is the kind of pattern that gets flagged here as a ‘cluster buy’ — a signal distinct from a single executive or fund making a routine purchase.
What the Filing Shows
Redmile Group’s purchase was made with the fund’s own capital in the open market, rather than through option exercises or other forms of compensation-linked acquisition. At $17.00 per share, the price reflects where Attovia stock was trading on the transaction date. The resulting position of nearly one million shares held directly underscores Redmile Group’s status as one of the company’s larger outside shareholders.
Readers interested in the other leg of this cluster can find more detail in our earlier coverage: Frazier Life Sciences Buys $10M of Attovia Therapeutics (ATTO), which covers a separate purchase disclosed around the same window.
Why Clustered Buying Draws Attention
Insider buying activity is tracked closely because it reflects decisions made with personal or fund capital, at prevailing market prices, rather than compensation tied to employment. When more than one insider buys within a tight timeframe, it tends to draw extra scrutiny from analysts and researchers who study these disclosures. Academic research on insider trading patterns has found that clustered purchases — multiple insiders buying the same stock in a short window — are statistically associated with periods of subsequent outperformance more often than isolated single-insider purchases, though such research describes historical tendencies across large samples of filings rather than predictions for any individual company.
This filing is a matter of public record, disclosed through the SEC’s Form 4 process, and is reported here for informational purposes as part of ongoing coverage of insider activity at Attovia Therapeutics.
→ See all ATTO coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.